Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Federal Trade Commission
Baxter
AstraZeneca
Fuji
McKesson

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 7,871,631

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,871,631
Title:Methods of inhibiting the lowering of antihuman TNF-.alpha. antibody
Abstract: The present invention provides an antihuman TNF-.alpha. antibody activity lowering inhibitor comprising a protein source(s) and/or carbohydrate source(s), in the treatment of inflammatory bowel syndrome with repeated administration of anti-TNF-.alpha. antibody; and a kit preparation wherein a freeze-dried antihuman TNF-.alpha. antibody and the activity lowering inhibitor in the above repeated administration of the anti-TNF-.alpha. antibody are separately contained in a plastic container so that they can communicate with each other. According to the present invention, in the drug therapy to the patients with inflammatory bowel syndrome, therapeutic agents which inhibit the inflammation for long periods without accompanying serious side effects can be provided.
Inventor(s): Matsumoto; Takayuki (Fukuoka, JP)
Assignee: Ajinomoto Co., Inc. (Tokyo, JP)
Application Number:12/562,728
Patent Claims:see list of patent claims

Details for Patent 7,871,631

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24 ➤ Sign Up Ajinomoto Co., Inc. (Tokyo, JP) 2024-03-01 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02 ➤ Sign Up Ajinomoto Co., Inc. (Tokyo, JP) 2024-03-01 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02 ➤ Sign Up Ajinomoto Co., Inc. (Tokyo, JP) 2024-03-01 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Daiichi Sankyo
UBS
Covington
Colorcon
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.